Results 81 to 90 of about 9,772 (228)
CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.Viloxazine, a serotonin–norepinephrine modulating agent, has been repurposed from an antidepressant to a novel non‐stimulant for ADHD. Its multimodal mechanism and Phase II/III trials demonstrate clinically meaningful symptom reduction with a distinct safety and interaction profile, offering an alternative for patients who cannot tolerate stimulants ...
Ghaith K. Mansour +4 more
wiley +1 more source
Sensitization of the Trigeminovascular Pathway: Perspective and Implications to Migraine Pathophysiology [PDF]
, 2012 Migraine headache is commonly associated with signs of exaggerated intracranial and extracranial mechanical sensitivities. Patients exhibiting signs of intracranial hypersensitivity testify that their headache throbs and that mundane physical activities ...
Bernstein, Carolyn A., Burstein, Rami
core +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.ABSTRACT Drug information centers (DICs) are institutions dedicated to providing independent and up‐to‐date information on medications and their usage to healthcare professionals. Here, we provide an update from the clinical‐pharmacological DIC of Hannover Medical School, covering the period from April 2022 to December 2024.
Johannes Heck +12 more
wiley +1 more source
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. [PDF]
, 2018 BackgroundIn a previous randomized, double-blind, proof-of-concept study in rapidly escalating migraine, a 3 mg dose of subcutaneous sumatriptan (DFN-11) was associated with fewer and shorter triptan sensations than a 6 mg dose.
Brand-Schieber, Elimor +3 more
core +1 more source
Headache management for the pain specialist [PDF]
, 2004 Headache is a common symptom caused by a wide variety of diseases. Primary headaches include migraine, cluster headache, tension-type headache and other less common diseases.
Ashkenazi, Avi, Silberstein, Stephen
core +2 more sources
Clinical and Translational Science, Volume 19, Issue 4, April 2026.ABSTRACT Ubrogepant (Ubrelvy), a CGRP receptor antagonist, is approved for acute treatment of migraine with or without aura in adults. Because ubrogepant treats a neurological condition, it is of interest to know central nervous system exposure. Ubrogepant concentrations in plasma and cerebrospinal fluid (CSF) were measured in participants with a ...
Ramesh R. Boinpally, Joel M. Trugman
wiley +1 more source
LifeObjective: To investigate the prescription patterns for patients aged 6–17 years with headaches in the REZULT database. Methods: We cross-sectionally investigated (Study 1) the pattern of prescription and the proportion of triptan overprescription (≥30 ...
Masahito Katsuki +10 more
doaj +1 more source
Self-medication with over-the-counter analgesics : a survey of patient characteristics and concerns about pain medication [PDF]
, 2019 Pain is a common reason for self-medication with over-the-counter (OTC) analgesics. However, this self-treating population has remained largely uncharacterized.
Adriaens, Els +10 more
core +2 more sources
Migraine - symptomatology, diagnostics, non-pharmacological and pharmacological procedures
Journal of Education, Health and Sport, 2018 Surprisingly, migraine is in the 3rd place of all diseases occurring in the world and affects 12% of the population, between the ages of 25 and 55. Migraine headaches significantly affect the quality of human life, while limiting proper bio-psycho-social
Kamila Tuzim +5 more
doaj
Arquivos de Neuro-Psiquiatria, 2009 Triptans, serotonin 5-HT1B/1D receptor agonists, more than revolutionizing the treatment of migraine, stimulated also ground breaking research that provided insights into the anatomy, physiology, and molecular pharmacology of migraine. This knowledge, in
Marcelo E. Bigal +2 more
doaj +1 more source